Inventiva SA ADR (IVA)
NASDAQ:IVA
Want to see IVA full AI Analyst Report?
IVA Stock Chart & Stats
$5.67
-$0.02(-0.90%)
At close: 4:00 PM EST
$5.67
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)673.34K
Market Cap
$824.32M
Enterprise Value$394.42M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 25, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume1,026,563
30 Day Avg. Volume673,339
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue87.99
Enterprise Value/Gross Profit249.52
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$15.75Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$4.18M
Bulls Say, Bears Say
Bulls Say
Phase III Enrollment CompletionCompleting NATiV3 enrollment and meeting target cohort sizes materially de-risks execution and statistical power for the pivotal readout. A well-powered, randomized 72-week trial reduces binary enrollment risk and supports regulatory planning and near-term milestone visibility over the next 2–6 months.
Strengthened Near-Term LiquidityA sizable cash balance and recent financings provide runway to advance the Phase III readout and invest in regulatory/commercial readiness. This funding flexibility improves the firm's ability to execute key development milestones and hiring plans over the medium term without immediate dilutive pressure.
Differentiated Clinical Profile & Regulatory DesignationsPhase II efficacy plus Breakthrough and Fast Track designations strengthen the product's regulatory and competitive positioning. The differentiated pan-PPAR profile and ancillary metabolic benefits support durable commercial differentiation and higher probability of favorable regulatory dialogue if Phase III confirms signals.
Bears Say
Weakened Balance SheetPersistent negative equity and rising debt materially constrain financial flexibility, increase covenant and counterparty risk, and limit strategic optionality. Over the next several months this structural leverage profile raises the likelihood of further refinancing needs or restrictive financing terms that can affect long-term plans.
Chronic Cash BurnHigh and growing operating cash burn reflects ongoing investment to sustain trials but erodes reserves absent new inflows. Persistent negative cash generation forces reliance on external financing to fund operations and pivotal milestones, increasing dilution and execution risk over the medium term.
Funding Contingent On Warrant/Tranche MechanicsDependence on contingent warrant exercises and tranche mechanics ties future liquidity to market and clinical events. That structural funding dependency increases the probability of transactional dilution or alternative financing under suboptimal terms, complicating planning for confirmatory trials and commercialization.
Inventiva News
IVA FAQ
What was Inventiva SA ADR’s price range in the past 12 months?
Inventiva SA ADR lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Inventiva SA ADR’s market cap?
Inventiva SA ADR’s market cap is $824.32M.
When is Inventiva SA ADR’s upcoming earnings report date?
Inventiva SA ADR’s upcoming earnings report date is Sep 25, 2026 which is in 96 days.
How were Inventiva SA ADR’s earnings last quarter?
Inventiva SA ADR released its earnings results on Mar 30, 2026. The company reported -$1.067 earnings per share for the quarter, missing the consensus estimate of -$0.279 by -$0.788.
Is Inventiva SA ADR overvalued?
According to Wall Street analysts Inventiva SA ADR’s price is currently Undervalued.
Does Inventiva SA ADR pay dividends?
Inventiva SA ADR does not currently pay dividends.
What is Inventiva SA ADR’s EPS estimate?
Inventiva SA ADR’s EPS estimate is -0.37.
How many shares outstanding does Inventiva SA ADR have?
Inventiva SA ADR has 236,280,200 shares outstanding.
What happened to Inventiva SA ADR’s price movement after its last earnings report?
Inventiva SA ADR reported an EPS of -$1.067 in its last earnings report, missing expectations of -$0.279. Following the earnings report the stock price went up 1.277%.
Which hedge fund is a major shareholder of Inventiva SA ADR?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (177.78% Upside)
$15.75 (177.78% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.28%
12-Months-Change
Fundamentals
Return on Equity
1870.38%
Trailing 12-Months
Asset Growth
138.07%
Trailing 12-Months
Company Description
Inventiva SA ADR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
IVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$15.75
▲(177.78% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.48% Mutual Funds
16.43% Other Institutional Investors
82.95% Public Companies and Individual Investors